Search
Carbon monoxide
go.drugbank.com/drugs/DB11588ApprovedInvestigationalSince 2002, FDA has favorably reviewed three GRAS notifications for carbon monoxide use in fresh meat packaging [L2537]. … The FDA classifies this drug as permitted as a food additive in the packaging and preparation of food products, while following the federal code of regulations [L2531].
Small ribosomal subunit protein RACK1
go.drugbank.com/bio_entities/BE0008967TargetHumansRegulates internalization of the muscarinic receptor CHRM2. Promotes apoptosis by increasing oligomerization of BAX and disrupting the interaction of BAX with the anti-apoptotic factor BCL2L.
Synonyms: Receptor for activated C kinase, Receptor for activated C kinase 1Invert sugar
go.drugbank.com/drugs/DB09344Experimental[A32124] Invert sugar is FDA approved since 1988 as a safe substance (GRAS).
T-lymphocyte activation antigen CD86
go.drugbank.com/bio_entities/BE0000846TargetHumansAlso acts as an inhibitor of T-cell activation by acting as a ligand for CTLA4, a decoy receptor, thereby blocking CD28-mediated T-cell priming (PubMed:11279501) … Acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T-cells by acting as a ligand for the CD28 receptor which is constitutively expressed on the cell surface of T-cells (PubMed:
Synonyms: CTLA-4 counter-receptor B7.2Integrin beta-1
go.drugbank.com/bio_entities/BE0003575TargetHumansIntegrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. … ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling (PubMed:29030430).
Synonyms: Fibronectin receptor subunit betaSerine/threonine-protein kinase TNNI3K
go.drugbank.com/bio_entities/BE0009401TargetHumansMay play a role in cardiac physiology
Synonyms: Cardiac ankyrin repeat kinaseGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalPacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,